Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05851443 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
A Phase 2 study of Moderate to Severe Asthma, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT05851443: Recruiting Phase 2 study of Moderate to Severe Asthma, sponsored by Incyte Corporation.
NCT05851443 is a Phase 2 study of Moderate to Severe Asthma that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 240 participants, below the 715-participant average among 3 other Moderate to Severe Asthma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05851443, a Phase 2 study of Moderate to Severe Asthma, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Primary Outcome
To assess the effect of povorcitinib on lung function (pre-BD FEV1) between baseline and week 24
Conditions Studied
Interventions
- OTHER placebo
- DRUG povorcitinib
- DRUG ICS-LABA
Study Locations (20)
Florida
- Qway Research - Hialeah
- Direct Helpers Research Center - Hialeah
- Care Research Inc - Miami
- Verus Clinical Research Corp - Miami
- Dr. de Armas Research Center, Llc - Miami
- Care Research Center, Inc - Miami
- Anderson Allergy and Asthma - Orlando
- Heuer Md Research Inc - Orlando
Michigan
- Henry Ford Hospital - Detroit
- Aa Medical Research Center - Flint
- Revive Research Institute - Southfield
New York
- Northwell Health Physician Partners - New Hyde Park
- Pioneer Clinical Research Ny - New York
- Montefiore Medical Center (Mmc) - The Bronx
California
- Kern Allergy Medical Clinic, Inc - Bakersfield
- Integrated Research of Inland, Inc - Upland
Georgia
- Advanced Clinical Research Atlanta - Atlanta
- Covenant Pulmonary Critical Care - East Point
Alabama
- Allervie Clinical Research - Birmingham
Illinois
- Northshore Medical Group - Glenview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
What NCT05851443 shows while recruiting
NCT05851443 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 715-participant average among 3 other Moderate to Severe Asthma trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Moderate to Severe Asthma appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT05851443 names 20 study sites across 7 states, led by Florida, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT05851443 about?
NCT05851443 is a clinical study titled "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma". The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
What is the current status of trial NCT05851443?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2023-07-11. Estimated completion is 2027-01-31.
What conditions does trial NCT05851443 study?
This clinical trial studies the following conditions: Moderate to Severe Asthma.
What interventions are being tested in trial NCT05851443?
The interventions under investigation include: placebo (OTHER), povorcitinib (DRUG), ICS-LABA (DRUG).
Who is sponsoring clinical trial NCT05851443?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05851443 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI